Objective: To evaluate the impact of
neoadjuvant chemotherapy on long-term
prognosis of
patients with borderline resectable
pancreatic cancer (BRPC) treated with combined
allograft revascularization.
Methods: The data of
patients with BRCP
who were treated at
Beijing Chaoyang
Hospital ,
Capital Medical
University from March 2016 to March 2021 were retrospectively analysed. Of 52
patients who underwent radical
surgery combined with
allograft revascularization in this study, there were 24
males and 28
females ,
aged (60.3±10.6) years old. These
patients were divided into two groups based on whether they received
neoadjuvant chemotherapy before
surgery . There were 19
patients in the
neoadjuvant chemotherapy group and 33
patients in the vascular replacement group.
Outpatient clinic and
telephone follow-up were used. The clinical data and prognostic differences between the two groups were then analysed.
Results: Of 52
patients who underwent
surgery successfully, 14
patients (26.9%) developed
postoperative complications . The
incidence of postoperative
pancreatic fistula was significantly lower in the
neoadjuvant chemotherapy group than the vascular replacement group (0 vs. 21.2%, P<0.05). The median survivals were 15 and 13 months in the
neoadjuvant chemotherapy and the vascular replacement groups, respectively, with a significant difference in cumulative postoperative
survival between the two groups ( P=0.039). For
patients with BRPC, CA19-9>400 U/ml ( RR=4.540, 95% CI 2.332-8.836, P<0.001) was an independent
risk factor for long-term
survival after
surgery .
Conclusions: Neoadjuvant chemotherapy reduced the
incidence of postoperative
pancreatic fistula and improved
survival prognosis in
patients with BRPC. A high preoperative
serum CA19-9 level was an independent
risk factor for long-term
survival in
patients with BRPC.